Macrophage Signaling Pathways in Health and Disease: From Bench to Bedside Applications

Abstract

Macrophages exhibit remarkable functional plasticity by dynamically polarizing into proinflammatory or antiinflammatory subsets in response to microenvironmental cues. This duality underpins their pivotal roles in immune defense, tissue homeostasis, and disease progression; however, the molecular mechanisms governing their polarization and crosstalk across various pathologies remain incompletely defined. This review systematically delineates macrophage biology, emphasizing the interplay between subset-specific signaling networks and their context-dependent activation in both health and disease. The heterogeneity of macrophages is characterized by detailing the distinctions between tissue-resident and monocyte-derived origins, as well as their polarization states. Core pathways regulating phagocytosis, tissue repair, immune modulation, and neuroprotection are dissected, along with their dysregulation in autoimmune disorders, neurodegeneration, cancers, and cardiovascular diseases. Notably, microenvironmental factors such as damage-associated molecular patterns, pathogen-associated molecular patterns, and metabolic intermediates dynamically reshape macrophage phenotypes through NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome activation or signal transducer and activator of transcription (STAT)-mediated transcriptional control. Preclinical and clinical evidence underscores potential therapeutic targets and emerging strategies. The significance of this review lies in its integrative analysis of signaling crosstalk, paradoxical pathway roles, and translational implications for precision therapies. These insights into macrophage functions and signaling pathways provide a robust foundation for future disease intervention and personalized medicine.

Keywords

injury and repair / macrophage / micro-environment / polarization / signaling pathways

References

[1] S. Su, J. Zhao, Y. Xing, et al., “Immune Checkpoint Inhibition Overcomes ADCP-induced Immunosuppression by Macrophages,” Cell 175, no. 2 (2018): 442-457. e23.

[2] V. Kiseleva, P. Vishnyakova, A. Elchaninov, et al., “Biochemical and Molecular Inducers and Modulators of M2 Macrophage Polarization in Clinical Perspective,” International Immunopharmacology 122 (2023): 110583.

[3] D. M. Underhill, S. Gordon, B. A. Imhof, et al., “Élie Metchnikoff (1845-1916): Celebrating 100 Years of Cellular Immunology and Beyond,” Nature Reviews Immunology 16, no. 10 (2016): 651-656.

[4] I. Vitale, G. Manic, L. M. Coussens, et al., “Macrophages and Metabolism in the Tumor Microenvironment,” Cell Metabolism 30, no. 1 (2019): 36-50.

[5] The Lancet. Editorial: Ballon v. bladder. The Lancet 1974; 2(7873): 141-142.

[6] T. A. Wynn and K. M. Vannella, “Macrophages in Tissue Repair, Regeneration, and Fibrosis,” Immunity 44, no. 3 (2016): 450-462.

[7] L. Honold and M. Nahrendorf, “Resident and Monocyte-derived Macrophages in Cardiovascular Disease,” Circulation Research 122, no. 1 (2018): 113-127.

[8] D. van der Heide, R. Weiskirchen, and R. Bansal, “Therapeutic Targeting of Hepatic Macrophages for the Treatment of Liver Diseases,” Frontiers in Immunology 10 (2019): 2852.

[9] M. Guilliams, F. Ginhoux, C. Jakubzick, et al., “Dendritic Cells, Monocytes and Macrophages: A Unified Nomenclature Based on Ontogeny,” Nature Reviews Immunology 14, no. 8 (2014): 571-578.

[10] R. M. Rodrigues, J. Boeckmans, and T. Vanhaecke, “Macrophages Clear out Necrotic Liver Lesions: A New Magic Trick Revealed,” Egastroenterology 1, no. 2 (2023): e100024.

[11] S. A. MacParland, J. C. Liu, X.-Z. Ma, et al., “Single Cell RNA Sequencing of human Liver Reveals Distinct Intrahepatic Macrophage Populations,” Nature Communications 9, no. 1 (2018): 4383.

[12] E. Papalexi and R. Satija, “Single-cell RNA Sequencing to Explore Immune Cell Heterogeneity,” Nature Reviews Immunology 18, no. 1 (2018): 35-45.

[13] Y. Wu and K. K. Hirschi, “Tissue-resident Macrophage Development and Function,” Frontiers in Cell and Developmental Biology 8 (2020): 617879.

[14] A. Guillot and F. Tacke, “Spatial Dimension of Macrophage Heterogeneity in Liver Diseases,” Egastroenterology 1, no. 1 (2023): e000003.

[15] Y. Ma, J. Wang, Y. Wang, et al., “The Biphasic Function of Microglia in Ischemic Stroke,” Progress in Neurobiology 157 (2017): 247-272.

[16] A. Dey, J. Allen, and P. A. Hankey-Giblin, “Ontogeny and Polarization of Macrophages in Inflammation: Blood Monocytes versus Tissue Macrophages,” Frontiers in Immunology 5 (2014): 683.

[17] M. Delfini, N. Stakenborg, M. F. Viola, et al., “Macrophages in the Gut: Masters in Multitasking,” Immunity 55, no. 9 (2022): 1530-1548.

[18] M. Casanova-Acebes, E. Dalla, A. M. Leader, et al., “Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells,” Nature 595, no. 7868 (2021): 578-584. https://doi.org/10.1038/s41586-021-03651-8.

[19] H. Ding, J.-J. Wang, X.-Y. Zhang, et al., “Lycium Barbarum Polysaccharide Antagonizes LPS-induced Inflammation by Altering the Glycolysis and Differentiation of Macrophages by Triggering the Degradation of PKM2,” Biological & Pharmaceutical Bulletin 44, no. 3 (2021): 379-388.

[20] P.-S. Liu, Y.-T. Chen, X. Li, et al., “CD40 signal Rewires Fatty Acid and Glutamine Metabolism for Stimulating Macrophage Anti-tumorigenic Functions,” Nature Immunology 24, no. 3 (2023): 452-462.

[21] H. Guo, Y. Song, F. Li, et al., “ACT001 suppressing M1 Polarization Against Inflammation via NF-κB and STAT1 Signaling Pathways Alleviates Acute Lung Injury in Mice,” International Immunopharmacology 110 (2022): 108944.

[22] A. Sica and A. Mantovani, “Macrophage Plasticity and Polarization: In Vivo Veritas,” Journal of Clinical Investigation 122, no. 3 (2012): 787-795.

[23] J. Rao, H. Wang, M. Ni, et al., “FSTL1 promotes Liver Fibrosis by Reprogramming Macrophage Function Through Modulating the Intracellular Function of PKM2,” Gut 71, no. 12 (2022): 2539-2550.

[24] Q. Zhang and M. Sioud, “Tumor-associated Macrophage Subsets: Shaping Polarization and Targeting,” International Journal of Molecular Sciences 24, no. 8 (2023): 7493.

[25] M. Stein, S. Keshav, N. Harris, et al., “Interleukin 4 Potently Enhances Murine Macrophage Mannose Receptor Activity: A Marker of Alternative Immunologic Macrophage Activation,” Journal of Experimental Medicine 176, no. 1 (1992): 287-292.

[26] L. Lefèvre, A. Galès, D. Olagnier, et al., “PPARγ Ligands Switched High Fat Diet-induced Macrophage M2b Polarization Toward M2a Thereby Improving Intestinal Candida Elimination,” PLoS ONE 5, no. 9 (2010): e12828.

[27] A. H. Sikkema, J. M. J. Stoffels, P. Wang, et al., “Fibronectin Aggregates Promote Features of a Classically and Alternatively Activated Phenotype in Macrophages,” Journal of Neuroinflammation 15, no. 1 (2018): 218.

[28] R. L. Gieseck, M. S. Wilson, and T. A. Wynn, “Type 2 Immunity in Tissue Repair and Fibrosis,” Nature Reviews Immunology 18, no. 1 (2018): 62-76.

[29] H. Li, Y. Meng, S. He, et al., “Macrophages, Chronic Inflammation, and Insulin Resistance,” Cells 11, no. 19 (2022): 3001.

[30] L.-X. Wang, S.-X. Zhang, H.-J. Wu, et al., “M2b macrophage Polarization and Its Roles in Diseases,” Journal of Leukocyte Biology 106, no. 2 (2019): 345-358.

[31] Q. Cao, N. Wang, J. Qi, et al., “Long Non‑Coding RNA‑GAS5 Acts as a Tumor Suppressor in Bladder Transitional Cell Carcinoma via Regulation of Chemokine (C‑C motif) Ligand 1 Expression,” Molecular Medicine Reports 13, no. 1 (2016): 27-34.

[32] A. Asai, K. Nakamura, M. Kobayashi, et al., “CCL1 released From M2b Macrophages Is Essentially Required for the Maintenance of Their Properties,” Journal of Leukocyte Biology 92, no. 4 (2012): 859-867.

[33] A. Shapouri-Moghaddam, S. Mohammadian, H. Vazini, et al., “Macrophage Plasticity, Polarization, and Function in Health and Disease,” Journal of Cellular Physiology 233, no. 9 (2018): 6425-6440.

[34] J. Null, Y.-S. Lai, H. T. Nguyen, et al., “MERTK+/Hi M2c Macrophages Induced by baicalin Alleviate Non-alcoholic Fatty Liver Disease,” International Journal of Molecular Sciences 22, no. 19 (2021): 10604.

[35] M. Horckmans, L. Ring, J. Duchene, et al., “Neutrophils Orchestrate Post-myocardial Infarction Healing by Polarizing Macrophages towards a Reparative Phenotype,” European Heart Journal 38, no. 3 (2017): 187-197.

[36] X. Huang, Y. Li, M. Fu, et al. Polarizing Macrophages in vitro. In: Rousselet G, editor. New York, NY: Springer New York. “Methods in Molecular Biology” (New York, NY): Springer New York, (2018): 119-126.

[37] G. Zizzo, B. A. Hilliard, M. Monestier, et al., “Efficient Clearance of Early Apoptotic Cells by human Macrophages Requires M2c Polarization and MerTK Induction,” Journal of Immunology 189, no. 7 (2012): 3508-3520.

[38] Q. Wang, H. Ni, L. Lan, et al., “Fra-1 Protooncogene Regulates IL-6 Expression in Macrophages and Promotes the Generation of M2d Macrophages,” Cell Research 20, no. 6 (2010): 701-712.

[39] W. Lai, C. Xian, M. Chen, et al., “Single-cell and Bulk Transcriptomics Reveals M2d Macrophages as a Potential Therapeutic Strategy for Mucosal Healing in Ulcerative Colitis,” International Immunopharmacology 121 (2023): 110509.

[40] X. Hu, J. Li, M. Fu, et al., “The JAK/STAT Signaling Pathway: From Bench to Clinic,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 402.

[41] S. Zhang, Y. Meng, L. Zhou, et al., “Targeting Epigenetic Regulators for Inflammation: Mechanisms and Intervention Therapy,” MedComm 3, no. 4 (2022): e173.

[42] L. B. Ivashkiv, “IFNγ: Signalling, Epigenetics and Roles in Immunity, Metabolism, Disease and Cancer Immunotherapy,” Nature Reviews Immunology 18, no. 9 (2018): 545-558.

[43] K. Kang, M. Bachu, S. H. Park, et al., “IFN-γ Selectively Suppresses a Subset of TLR4-activated Genes and Enhancers to Potentiate Macrophage Activation,” Nature Communications 10, no. 1 (2019): 3320.

[44] D. E. Johnson, R. A. O'Keefe, and J. R. Grandis, “Targeting the IL-6/JAK/STAT3 Signalling Axis in Cancer,” Nature Reviews Clinical oncology 15, no. 4 (2018): 234-248.

[45] M. S. Hayden and S. Ghosh, “Shared Principles in NF-kappaB Signaling,” Cell 132, no. 3 (2008): 344-362.

[46] C. Liu, F. Hu, G. Jiao, et al., “Dental Pulp Stem Cell-derived Exosomes Suppress M1 Macrophage Polarization Through the ROS-MAPK-NFκB P65 Signaling Pathway After Spinal Cord Injury,” Journal of Nanobiotechnology 20, no. 1 (2022): 65.

[47] H.-F. Zhou, C. Yang, J.-Y. Li, et al., “Quercetin Serves as the Major Component of Xiang-lian Pill to Ameliorate Ulcerative Colitis via Tipping the Balance of STAT1/PPARγ and Dictating the Alternative Activation of Macrophage,” Journal of Ethnopharmacology 313 (2023): 116557.

[48] T. Zhang, C. Ma, Z. Zhang, et al., “NF-κB Signaling in Inflammation and Cancer,” MedComm 2, no. 4 (2021): 618-653.

[49] V. Y.-F. Wang, Y. Li, D. Kim, et al., “Bcl3 phosphorylation by Akt, Erk2, and IKK Is Required for Its Transcriptional Activity,” Molecular Cell 67, no. 3 (2017): 484-497. e5.

[50] S. Khanmohammadi and M. S. Kuchay, “Toll-Like Receptors and Metabolic (dysfunction)-associated Fatty Liver Disease,” Pharmacological Research 185 (2022): 106507.

[51] K. Miura, E. Seki, H. Ohnishi, et al., “Role of Toll-Like Receptors and Their Downstream Molecules in the Development of Nonalcoholic Fatty Liver Disease,” Gastroenterology Research and Practice 2010 (2010): 362847.

[52] J. Petrasek, T. Csak, and G. Szabo, “Toll-Like Receptors in Liver Disease,” Advances in Clinical Chemistry 59 (2013): 155-201.

[53] C. S. Mantsounga, C. Lee, J. Neverson, et al., “Macrophage IL-1β Promotes Arteriogenesis by Autocrine STAT3- and NF-κB-mediated Transcription of Pro-angiogenic VEGF-A,” Cell Reports 38, no. 5 (2022): 110309.

[54] C. Porta, M. Rimoldi, G. Raes, et al., “Tolerance and M2 (alternative) Macrophage Polarization Are Related Processes Orchestrated by p50 Nuclear Factor kappaB,” PNAS 106, no. 35 (2009): 14978-14983.

[55] Y. Zhang, M. Xia, K. Jin, et al., “Function of the c-Met Receptor Tyrosine Kinase in Carcinogenesis and Associated Therapeutic Opportunities,” Molecular Cancer 17, no. 1 (2018): 45.

[56] T. Ersahin, N. Tuncbag, and R. Cetin-Atalay, “The PI3K/AKT/mTOR Interactive Pathway,” Molecular Biosystems 11, no. 7 (2015): 1946-1954.

[57] S.-J. Zhao, F.-Q. Kong, J. Jie, et al., “Macrophage MSR1 Promotes BMSC Osteogenic Differentiation and M2-Like Polarization by Activating PI3K/AKT/GSK3β/β-catenin Pathway,” Theranostics 10, no. 1 (2020): 17-35.

[58] J. Liu, F. Xing, Q. Fu, et al., “hUC-MSCs Exosomal miR-451 Alleviated Acute Lung Injury by Modulating Macrophage M2 Polarization via Regulating MIF-PI3K-AKT Signaling Pathway,” Environmental Toxicology 37, no. 12 (2022): 2819-2831.

[59] Y. Wang, X. Zhang, J. Wang, et al., “Inflammatory Periodontal Ligament Stem Cells Drive M1 Macrophage Polarization via Exosomal miR-143-3p-mediated Regulation of PI3K/AKT/NF-κB Signaling,” Stem Cells 41, no. 2 (2023): 184-199.

[60] Z. Zhang, S. Peng, T. Xu, et al., “Retinal Microenvironment-protected rhein-GFFYE Nanofibers Attenuate Retinal Ischemia-reperfusion Injury via Inhibiting Oxidative Stress and Regulating Microglial/Macrophage M1/M2 Polarization,” Advancement of Science 10, no. 30 (2023): 2302909.

[61] X. Xu, L. Cui, L. Zhang, et al., “Saikosaponin D Modulates the Polarization of Tumor-associated Macrophages by Deactivating the PI3K/AKT/mTOR Pathway in Murine Models of Pancreatic Cancer,” International Immunopharmacology 122 (2023): 110579.

[62] T. Lawrence and G. Natoli, “Transcriptional Regulation of Macrophage Polarization: Enabling Diversity With Identity,” Nature Reviews Immunology 11, no. 11 (2011): 750-761.

[63] T. Tamura, H. Yanai, D. Savitsky, et al., “The IRF family Transcription Factors in Immunity and Oncogenesis,” Annual Review of Immunology 26 (2008): 535-584.

[64] R. Zhang, Q. Li, P. Y. Chuang, et al., “Regulation of Pathogenic Th17 Cell Differentiation by IL-10 in the Development of Glomerulonephritis,” American Journal of Pathology 183, no. 2 (2013): 402-412.

[65] Z. Ahmad, W. Kahloan, and E. D. Rosen, “Transcriptional Control of Metabolism by Interferon Regulatory Factors,” Nature reviews Endocrinology 20, no. 10 (2024): 573-587.

[66] R. Günthner and H.-J. Anders, “Interferon-regulatory Factors Determine Macrophage Phenotype Polarization,” Mediators of Inflammation 2013 (2013): 731023.

[67] Y.-J. Chen, J. Li, N. Lu, et al., “Interferon Regulatory Factors: A Key to Tumour Immunity,” International Immunopharmacology 49 (2017): 1-5.

[68] M. Sharifiaghdam, E. Shaabani, R. Faridi-Majidi, et al., “Macrophages as a Therapeutic Target to Promote Diabetic Wound Healing,” Molecular Therapy 30, no. 9 (2022): 2891-2908.

[69] G. Lu, R. Zhang, S. Geng, et al., “Myeloid Cell-derived Inducible Nitric Oxide Synthase Suppresses M1 Macrophage Polarization,” Nature Communications 6 (2015): 6676.

[70] J. Eguchi, X. Kong, M. Tenta, et al., “Interferon Regulatory Factor 4 Regulates Obesity-induced Inflammation Through Regulation of Adipose Tissue Macrophage Polarization,” Diabetes 62, no. 10 (2013): 3394-3403.

[71] I. Espinoza and L. Miele, “Deadly Crosstalk: Notch Signaling at the Intersection of EMT and Cancer Stem Cells,” Cancer Letters 341, no. 1 (2013): 41-45.

[72] R. A. Kovall, B. Gebelein, D. Sprinzak, et al., “The Canonical Notch Signaling Pathway: Structural and Biochemical Insights Into Shape, Sugar, and Force,” Developmental Cell 41, no. 3 (2017): 228-241.

[73] P. Kongkavitoon, P. Butta, A. Sanpavat, et al., “Regulation of Periostin Expression by Notch Signaling in Hepatocytes and Liver Cancer Cell Lines,” Biochemical and Biophysical Research Communications 506, no. 3 (2018): 739-745.

[74] S. F. Aval, H. Lotfi, R. Sheervalilou, et al., “Tuning of Major Signaling Networks (TGF-β, Wnt, Notch and Hedgehog) by miRNAs in human Stem Cells Commitment to Different Lineages: Possible Clinical Application,” Biomedicine & Pharmacotherapy 91 (2017): 849-860.

[75] G. Wu, G. Wilson, J. George, et al., “Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer,” Current Gene Therapy 15, no. 2 (2015): 171-181.

[76] E. Keewan and S. A. Naser, “The Role of Notch Signaling in Macrophages During Inflammation and Infection: Implication in Rheumatoid Arthritis?,” Cells 9, no. 1 (2020): 111.

[77] W. Wongchana, P. Kongkavitoon, P. Tangtanatakul, et al., “Notch Signaling Regulates the Responses of Lipopolysaccharide-stimulated Macrophages in the Presence of Immune Complexes,” PLoS ONE 13, no. 6 (2018): e0198609.

[78] E. Keewan and S. A. Naser, “Notch-1 Signaling Modulates Macrophage Polarization and Immune Defense Against Mycobacterium Avium Paratuberculosis Infection in Inflammatory Diseases,” Microorganisms 8, no. 7 (2020): 1006.

[79] H. Xu, J. Zhu, S. Smith, et al., “Notch-RBP-J Signaling Regulates the Transcription Factor IRF8 to Promote Inflammatory Macrophage Polarization,” Nature Immunology 13, no. 7 (2012): 642-650.

[80] Y.-C. Wang, F. He, F. Feng, et al., “Notch Signaling Determines the M1 versus M2 Polarization of Macrophages in Antitumor Immune Responses,” Cancer Research 70, no. 12 (2010): 4840-4849.

[81] W. Guo, Z. Li, G. Anagnostopoulos, et al., “Notch Signaling Regulates Macrophage-mediated Inflammation in Metabolic Dysfunction-associated Steatotic Liver Disease,” Immunity 57, no. 10 (2024): 2310-2327. e6.

[82] F. Vieceli Dalla Sega, F. Fortini, G. Aquila, et al., “Notch Signaling Regulates Immune Responses in Atherosclerosis,” Frontiers in immunology 10 (2019): 1130.

[83] J. Xu, F. Chi, and H. Tsukamoto, “Notch Signaling and M1 Macrophage Activation in Obesity-alcohol Synergism,” Clinics and Research in Hepatology and Gastroenterology 39, no. Suppl 10 1 (2015): S24-S28.

[84] S. Gordon, “Phagocytosis: An Immunobiologic Process,” Immunity 44, no. 3 (2016): 463-475.

[85] M. A. Sanjuan, C. P. Dillon, S. W. G. Tait, et al., “Toll-Like Receptor Signalling in Macrophages Links the Autophagy Pathway to Phagocytosis,” Nature 450, no. 7173 (2007): 1253-1257.

[86] D. Li, R. Wei, X. Zhang, et al., “Gut Commensal Metabolite Rhamnose Promotes Macrophages Phagocytosis by Activating SLC12A4 and Protects Against Sepsis in Mice,” Acta Pharmaceutica Sinica B 14, no. 7 (2024): 3068-3085.

[87] S. Duan and J. C. Paulson, “Siglecs as Immune Cell Checkpoints in Disease,” Annual Review of Immunology 38 (2020): 365-395.

[88] X. Zhuang, J. Ma, S. Xu, et al., “SHP-1 Suppresses Endotoxin-induced Uveitis by Inhibiting the TAK1/JNK Pathway,” Journal of Cellular and Molecular Medicine 25, no. 1 (2021): 147-160.

[89] A. A. Barkal, R. E. Brewer, M. Markovic, et al., “CD24 signalling Through Macrophage Siglec-10 Is a Target for Cancer Immunotherapy,” Nature 572, no. 7769 (2019): 392-396.

[90] J. Á. Freile, N. Ustyanovska Avtenyuk, M. G. Corrales, et al., “CD24 is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma,” Biomedicines 10, no. 5 (2022): 1175.

[91] S. M. G. Hayat, V. Bianconi, M. Pirro, et al., “CD47: Role in the Immune System and Application to Cancer Therapy,” Cellular Oncology 43, no. 1 (2020): 19-30.

[92] Y. Fujioka, T. Matozaki, T. Noguchi, et al., “A Novel Membrane Glycoprotein, SHPS-1, That Binds the SH2-domain-containing Protein Tyrosine Phosphatase SHP-2 in Response to Mitogens and Cell Adhesion,” Molecular and Cellular Biology 16, no. 12 (1996): 6887-6899.

[93] A. Kharitonenkov, Z. Chen, I. Sures, et al., “A family of Proteins That Inhibit Signalling Through Tyrosine Kinase Receptors,” Nature 386, no. 6621 (1997): 181-186.

[94] A. N. Barclay and T. K. Van den Berg, “The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target,” Annual Review of Immunology 32 (2014): 25-50.

[95] R. K. Tsai and D. E. Discher, “Inhibition of ‘Self’ engulfment Through Deactivation of Myosin-II at the Phagocytic Synapse Between human Cells,” Journal of Cell Biology 180, no. 5 (2008): 989-1003.

[96] J. F. Timms, K. D. Swanson, A. Marie-Cardine, et al., “SHPS-1 Is a Scaffold for Assembling Distinct Adhesion-regulated Multi-protein Complexes in Macrophages,” Current Biology 9, no. 16 (1999): 927-930.

[97] A. Das, M. Sinha, S. Datta, et al., “Monocyte and Macrophage Plasticity in Tissue Repair and Regeneration,” American Journal of Pathology 185, no. 10 (2015): 2596-2606.

[98] Q. Zhang, M. Raoof, Y. Chen, et al., “Circulating Mitochondrial DAMPs Cause Inflammatory Responses to Injury,” Nature 464, no. 7285 (2010): 104-107.

[99] T. Kisseleva and D. Brenner, “Molecular and Cellular Mechanisms of Liver Fibrosis and Its Regression,” Nature reviews Gastroenterology & Hepatology 18, no. 3 (2021): 151-166.

[100] S. Nattel, “Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation,” JACC: Clinical Electrophysiology 3, no. 5 (2017): 425-435.

[101] Y. Wei, H. Guo, S. Chen, et al., “Regulation of Macrophage Activation by Lactylation in Lung Disease,” Frontiers in Immunology 15 (2024): 1427739.

[102] P. M.-K. Tang, D. J. Nikolic-Paterson, and H.-Y. Lan, “Macrophages: Versatile Players in Renal Inflammation and Fibrosis,” Nature Reviews Nephrology 15, no. 3 (2019): 144-158.

[103] L. Yan, J. Wang, X. Cai, et al., “Macrophage Plasticity: Signaling Pathways, Tissue Repair, and Regeneration,” MedComm 5, no. 8 (2024): e658.

[104] L. Guo, H. Akahori, E. Harari, et al., “CD163+ macrophages Promote Angiogenesis and Vascular Permeability Accompanied by Inflammation in Atherosclerosis,” Journal of Clinical Investigation 128, no. 3 (2018): 1106-1124.

[105] X. Cui, R.-T. Tan Morales, W. Qian, et al., “Corrigendum to ‘Hacking Macrophage-associated Immunosuppression for Regulating Glioblastoma Angiogenesis’ [Biomater. 161 (2018) 164-178],” Biomaterials 287 (2022): 121667.

[106] Y. Yang, Z. Guo, W. Chen, et al., “M2 macrophage-derived Exosomes Promote Angiogenesis and Growth of Pancreatic Ductal Adenocarcinoma by Targeting E2F2,” Molecular Therapy 29, no. 3 (2021): 1226-1238.

[107] X. Guo, H. Zhang, C. He, et al., “RUNX1 promotes Angiogenesis in Colorectal Cancer by Regulating the Crosstalk Between Tumor Cells and Tumor Associated Macrophages,” Biomarker Research 12, no. 1 (2024): 29.

[108] T. Zeng, K. Sun, L. Mai, et al., “Extracellular Vesicle-associated miR-ERIA Exerts the Anti-angiogenic Effect of Macrophages in Diabetic Wound Healing,” Diabetes 74, no. 4 (2025): 596-610.

[109] R. Ramalho, M. Rao, C. Zhang, et al., “Immunometabolism: New Insights and Lessons From Antigen-directed Cellular Immune Responses,” Seminars in Immunopathology 42, no. 3 (2020): 279-313.

[110] N. Luque-Campos, F. A. Bustamante-Barrientos, C. Pradenas, et al., “The Macrophage Response Is Driven by Mesenchymal Stem Cell-mediated Metabolic Reprogramming,” Frontiers in Immunology 12 (2021): 624746.

[111] E. M. Pålsson-McDermott and L. A. J. O'Neill, “Targeting Immunometabolism as an Anti-inflammatory Strategy,” Cell Research 30, no. 4 (2020): 300-314.

[112] M. Lacroix, R. Riscal, G. Arena, et al., “Metabolic Functions of the Tumor Suppressor p53: Implications in Normal Physiology, Metabolic Disorders, and Cancer,” Molecular Metabolism 33 (2020): 2-22.

[113] K. Mehla and P. K. Singh, “Metabolic Regulation of Macrophage Polarization in Cancer,” Trends in cancer 5, no. 12 (2019): 822-834.

[114] J. Behmoaras, “The Versatile Biochemistry of Iron in Macrophage Effector Functions,” Febs Journal 288, no. 24 (2021): 6972-6989.

[115] H. Xiao, Y. Guo, B. Li, et al., “M2-Like Tumor-associated Macrophage-targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy With Low Immune Side Effects,” ACS Central Science 6, no. 7 (2020): 1208-1222.

[116] M. Läsche, G. Emons, and C. Gründker, “Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death,” Frontiers in Oncology 10 (2020): 409.

[117] M. Bosch, M. Sánchez-Álvarez, A. Fajardo, et al., “Mammalian Lipid Droplets Are Innate Immune Hubs Integrating Cell Metabolism and Host Defense,” Science 370, no. 6514 (2020): eaay8085.

[118] L. Fortuny and C. Sebastián, “Sirtuins as Metabolic Regulators of Immune Cells Phenotype and Function,” Genes 12, no. 11 (2021): 1698.

[119] S. Chen, A. Saeed, Q. Liu, et al., “Macrophages in Immunoregulation and Therapeutics,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 207.

[120] L. Yang, M.-F. Fu, H.-Y. Wang, et al., “Research Advancements in the Interplay Between T3 and Macrophages,” Current Medical Science 44, no. 5 (2024): 883-889.

[121] M. Tang, B. Chen, H. Xia, et al., “pH-gated Nanoparticles Selectively Regulate Lysosomal Function of Tumour-associated Macrophages for Cancer Immunotherapy,” Nature Communications 14, no. 1 (2023): 5888.

[122] Y. Wang, Y. Fan, X. Zhang, et al., “In Situ Production and Precise Release of Bioactive GM-CSF and siRNA by Engineered Bacteria for Macrophage Reprogramming in Cancer Immunotherapy,” Biomaterials 317 (2025): 123037.

[123] H. Gao, J. Di, B. H. Clausen, et al., “Distinct Myeloid Population Phenotypes Dependent on TREM2 Expression Levels Shape the Pathology of Traumatic versus Demyelinating CNS Disorders,” Cell Reports 42, no. 6 (2023): 112629.

[124] Y.-Z. Lu, B. Nayer, S. K. Singh, et al., “CGRP Sensory Neurons Promote Tissue Healing via Neutrophils and Macrophages,” Nature 628, no. 8008 (2024): 604-611.

[125] R. Feng, V. Muraleedharan Saraswathy, M. H. Mokalled, et al., “Self-renewing Macrophages in Dorsal Root Ganglia Contribute to Promote Nerve Regeneration,” PNAS 120, no. 7 (2023): e2215906120.

[126] C. G. Peace, S. M. O'Carroll, and L. A. J. O'Neill, “Fumarate Hydratase as a Metabolic Regulator of Immunity,” Trends in Cell Biology 34, no. 6 (2024): 442-450.

[127] A. Hooftman, C. G. Peace, D. G. Ryan, et al., “Macrophage Fumarate Hydratase Restrains mtRNA-mediated Interferon Production,” Nature 615, no. 7952 (2023): 490-498.

[128] M. Arabpour, A. Saghazadeh, and N. Rezaei, “Anti-inflammatory and M2 Macrophage Polarization-promoting Effect of Mesenchymal Stem Cell-derived Exosomes,” International Immunopharmacology 97 (2021): 107823.

[129] A. Aguzzi, B. A. Barres, and M. L. Bennett, “Microglia: Scapegoat, Saboteur, or Something Else?,” Science 339, no. 6116 (2013): 156-161.

[130] C. D'Mello, K. Riazi, T. Le, et al., “P-selectin-mediated Monocyte-cerebral Endothelium Adhesive Interactions Link Peripheral Organ Inflammation to Sickness Behaviors,” The Journal of Neuroscience 33, no. 37 (2013): 14878-14888.

[131] C. N. Parkhurst, G. Yang, I. Ninan, et al., “Microglia Promote Learning-dependent Synapse Formation Through Brain-derived Neurotrophic Factor,” Cell 155, no. 7 (2013): 1596-1609.

[132] W. M. Song and M. Colonna, “The Identity and Function of Microglia in Neurodegeneration,” Nature Immunology 19, no. 10 (2018): 1048-1058.

[133] F. Matheis, P. A. Muller, C. L. Graves, et al., “Adrenergic Signaling in Muscularis Macrophages Limits Infection-induced Neuronal Loss,” Cell 180, no. 1 (2020): 64-78. e16.

[134] X. Yin, K. Kim, H. Suetsugu, et al., “Meta-analysis of 208370 East Asians Identifies 113 Susceptibility Loci for Systemic Lupus Erythematosus,” Annals of the Rheumatic Diseases 80, no. 5 (2021): 632-640.

[135] M. D. Catalina, K. A. Owen, A. C. Labonte, et al., “The Pathogenesis of Systemic Lupus Erythematosus: Harnessing Big Data to Understand the Molecular Basis of Lupus,” Journal of Autoimmunity 110 (2020): 102359.

[136] S. V. Parikh, S. Almaani, S. Brodsky, et al., “Update on Lupus Nephritis: Core Curriculum 2020,” American Journal of Kidney Diseases 76, no. 2 (2020): 265-281.

[137] Y. Xin, C. Gao, L. Wang, et al., “Lipopolysaccharide Released From Gut Activates Pyroptosis of Macrophages via Caspase 11-Gasdermin D Pathway in Systemic Lupus Erythematosus,” MedComm 5, no. 6 (2024): e610.

[138] C. Deng, Q. Zhang, P. He, et al., “Targeted Apoptosis of Macrophages and Osteoclasts in Arthritic Joints Is Effective Against Advanced Inflammatory Arthritis,” Nature Communications 12, no. 1 (2021): 2174.

[139] P. Di Benedetto, P. Ruscitti, Z. Vadasz, et al., “Macrophages With Regulatory Functions, a Possible New Therapeutic Perspective in Autoimmune Diseases,” Autoimmunity Reviews 18, no. 10 (2019): 102369.

[140] L. C. Davies, S. J. Jenkins, J. E. Allen, et al., “Tissue-resident Macrophages,” Nature Immunology 14, no. 10 (2013): 986-995.

[141] S. Culemann, A. Grüneboom, J. Á. Nicolás-Ávila, et al., “Locally Renewing Resident Synovial Macrophages Provide a Protective Barrier for the Joint,” Nature 572, no. 7771 (2019): 670-675.

[142] S. Jain, T.-H. Tran, and M. Amiji, “Macrophage Repolarization With Targeted Alginate Nanoparticles Containing IL-10 Plasmid DNA for the Treatment of Experimental Arthritis,” Biomaterials 61 (2015): 162-177.

[143] N. Jia, Y. Gao, M. Li, et al., “Metabolic Reprogramming of Proinflammatory Macrophages by Target Delivered Roburic Acid Effectively Ameliorates Rheumatoid Arthritis Symptoms,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 280.

[144] Y. Okabe and R. Medzhitov, “Tissue Biology Perspective on Macrophages,” Nature Immunology 17, no. 1 (2016): 9-17.

[145] S. Watanabe, M. Alexander, A. V. Misharin, et al., “The Role of Macrophages in the Resolution of Inflammation,” Journal of Clinical Investigation 129, no. 7 (2019): 2619-2628.

[146] J. S. Smolen, D. Aletaha, and I. B. McInnes, “Rheumatoid Arthritis,” The Lancet 388, no. 10055 (2016): 2023-2038.

[147] P. P. Tak, T. J. Smeets, M. R. Daha, et al., “Analysis of the Synovial Cell Infiltrate in Early Rheumatoid Synovial Tissue in Relation to Local Disease Activity,” Arthritis and Rheumatism 40, no. 2 (1997): 217-225.

[148] Y. Hao, S. Hao, E. Andersen-Nissen, et al., “Integrated Analysis of Multimodal Single-cell Data,” Cell 184, no. 13 (2021): 3573-3587. e29.

[149] J. D. Kean, J. Kaufman, J. Lomas, et al., “A Randomized Controlled Trial Investigating the Effects of a Special Extract of Bacopa monnieri (CDRI 08) on Hyperactivity and Inattention in Male Children and Adolescents: BACHI Study Protocol (ANZCTRN12612000827831),” Nutrients 7, no. 12 (2015): 9931-9945.

[150] X. Wu, J. A. Miller, B. T. K. Lee, et al., “Reducing Microglial Lipid Load Enhances β Amyloid Phagocytosis in an Alzheimer's Disease Mouse Model,” Science Advances 11, no. 6 (2025): eadq6038.

[151] Y. Wang, M. Cella, K. Mallinson, et al., “TREM2 lipid Sensing Sustains the Microglial Response in an Alzheimer's disease Model,” Cell 160, no. 6 (2015): 1061-1071.

[152] A. Griciuc, S. Patel, A. N. Federico, et al., “TREM2 acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease,” Neuron 103, no. 5 (2019): 820-835. e7.

[153] E. N. Wilson, C. Wang, M. S. Swarovski, et al., “TREM1 disrupts Myeloid Bioenergetics and Cognitive Function in Aging and Alzheimer Disease Mouse Models,” Nature Neuroscience 27, no. 5 (2024): 873-885.

[154] R. Dvir-Szternfeld, G. Castellani, M. Arad, et al., “Alzheimer's Disease Modification Mediated by Bone Marrow-derived Macrophages via a TREM2-independent Pathway in Mouse Model of Amyloidosis,” Nat Aging 2, no. 1 (2022): 60-73.

[155] S. Moonen, M. J. Koper, E. Van Schoor, et al., “Pyroptosis in Alzheimer's Disease: Cell Type-specific Activation in Microglia, Astrocytes and Neurons,” Acta Neuropathologica, (Berlin) 145, no. 2 (2023): 175-195.

[156] Alzheimer's & Dementia. 2023 Alzheimer's Disease Facts and Figures. Alzheimers Dement 2023; 19(4): 1598-1695.

[157] S. Su, Q. Liu, J. Chen, et al., “A Positive Feedback Loop Between Mesenchymal-Like Cancer Cells and Macrophages Is Essential to Breast Cancer Metastasis,” Cancer Cell 25, no. 5 (2014): 605-620.

[158] C. Wei, C. Yang, S. Wang, et al., “Crosstalk Between Cancer Cells and Tumor Associated Macrophages Is Required for Mesenchymal Circulating Tumor Cell-mediated Colorectal Cancer Metastasis,” Molecular Cancer 18, no. 1 (2019): 64.

[159] Y. Yin, S. Yao, Y. Hu, et al., “The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer Through Macrophage-derived IL6,” Clinical Cancer Research 23, no. 23 (2017): 7375-7387.

[160] X. Wang, G. Luo, K. Zhang, et al., “Hypoxic Tumor-derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis,” Cancer Research 78, no. 16 (2018): 4586-4598.

[161] H. Li, P. Yang, J. Wang, et al., “HLF Regulates Ferroptosis, Development and Chemoresistance of Triple-negative Breast Cancer by Activating Tumor Cell-macrophage Crosstalk,” Journal of Hematology & Oncology 15, no. 1 (2022): 2.

[162] E. Timperi, P. Gueguen, M. Molgora, et al., “Lipid-associated Macrophages Are Induced by Cancer-associated Fibroblasts and Mediate Immune Suppression in Breast Cancer,” Cancer Research 82, no. 18 (2022): 3291-3306.

[163] J. Xia, L. Zhang, X. Peng, et al., “IL1R2 blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-negative Breast Cancer,” Cancer Research 84, no. 14 (2024): 2282-2296.

[164] S. Singh, N. Lee, D. A. Pedroza, et al., “Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-negative Breast Cancer,” Cancer Research 82, no. 12 (2022): 2281-2297.

[165] Y. Yan, D. Sun, J. Hu, et al., “Multi-omic Profiling Highlights Factors Associated With Resistance to Immuno-chemotherapy in Non-small-cell Lung Cancer,” Nature Genetics 57, no. 1 (2025): 126-139.

[166] G. Chiesa, M. Torre, M. Ravini, et al., “[Agenesis of the right pulmonary artery and systemic pulmonary vascularization in 4 cases observed in childhood],” Minerva Chirurgica 42, no. 1-2 (1987): 39-44.

[167] C. Wang, Y. Li, L. Wang, et al., “SPP1 represents a Therapeutic Target That Promotes the Progression of Oesophageal Squamous Cell Carcinoma by Driving M2 Macrophage Infiltration,” British Journal of Cancer 130, no. 11 (2024): 1770-1782.

[168] Y. Zheng, Z. Chen, Y. Han, et al., “Immune Suppressive Landscape in the human Esophageal Squamous Cell Carcinoma Microenvironment,” Nature Communications 11, no. 1 (2020): 6268.

[169] H. Sakamoto, Y.-I. Koma, N. Higashino, et al., “PAI-1 Derived From Cancer-associated Fibroblasts in Esophageal Squamous Cell Carcinoma Promotes the Invasion of Cancer Cells and the Migration of Macrophages,” Laboratory Investigation; A Journal of Technical Methods and Pathology 101, no. 3 (2021): 353-368.

[170] X. Zhou, Z. Yan, J. Hou, et al., “The Hippo-YAP Signaling Pathway Drives CD24-mediated Immune Evasion in Esophageal Squamous Cell Carcinoma via Macrophage Phagocytosis,” Oncogene 43, no. 7 (2024): 495-510.

[171] G. Taha, L. Ezra, and N. Abu-Freha, “Hepatitis C Elimination: Opportunities and Challenges in 2023,” Viruses. 15, no. 7 (2023): 1413.

[172] D. Lavanchy, “Evolving Epidemiology of hepatitis C Virus,” Clinical Microbiology and Infection 17, no. 2 (2011): 107-115.

[173] C. P. Chan, H. Uemura, T. H. Kwan, et al., “Review on the Molecular Epidemiology of Sexually Acquired hepatitis C Virus Infection in the Asia-Pacific region,” Journal of the International AIDS Society 23, no. 9 (2020): e25618.

[174] C. Trépo, H. L. Y. Chan, and A. Lok, “Hepatitis B Virus Infection,” The Lancet 384, no. 9959 (2014): 2053-2063.

[175] O. Paccoud, L. Surgers, and K. Lacombe, “[Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach],” Revue de Médecine Interne 40, no. 9 (2019): 590-598.

[176] C.-H. Liu and J.-H. Kao, “Acute hepatitis C Virus Infection: Clinical Update and Remaining Challenges,” Clinical and Molecular Hepatology 29, no. 3 (2023): 623-642.

[177] D. I. Chigbu, R. Loonawat, M. Sehgal, et al., “Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence,” Cells 8, no. 4 (2019): 376.

[178] M. H. Nguyen, G. Wong, E. Gane, et al., “Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy,” Clinical Microbiology Reviews 33, no. 2 (2020): e00046-19.

[179] C. L. Day, G. M. Lauer, G. K. Robbins, et al., “Broad Specificity of Virus-specific CD4+ T-helper-cell Responses in Resolved hepatitis C Virus Infection,” Journal of Virology 76, no. 24 (2002): 12584-12595.

[180] T. Tu and M. W. Douglas, “Hepatitis B Virus Infection: From Diagnostics to Treatments,” Viruses. 12, no. 12 (2020): 1366.

[181] C. Mehrfeld, S. Zenner, M. Kornek, et al., “The Contribution of Non-professional Antigen-presenting Cells to Immunity and Tolerance in the Liver,” Frontiers in Immunology 9 (2018): 635.

[182] D. Loureiro, I. Tout, S. Narguet, et al., “Mitochondrial Stress in Advanced Fibrosis and Cirrhosis Associated With Chronic hepatitis B, Chronic hepatitis C, or Nonalcoholic Steatohepatitis,” Hepatology 77, no. 4 (2023): 1348-1365.

[183] N. Nasser, P. Tonnerre, A. Mansouri, et al., “Hepatitis-B Virus: Replication Cycle, Targets, and Antiviral Approaches,” Current Opinion in Virology 63 (2023): 101360.

[184] R. Lozano, M. Naghavi, K. Foreman, et al., “Global and Regional Mortality From 235 Causes of Death for 20 Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010,” The Lancet 380, no. 9859 (2012): 2095-2128.

[185] J. Rehm, A. V. Samokhvalov, and K. D. Shield, “Global Burden of Alcoholic Liver Diseases,” Journal of Hepatology 59, no. 1 (2013): 160-168.

[186] A. K. Singal, R. Bataller, J. Ahn, et al., “ACG Clinical Guideline: Alcoholic Liver Disease,” American Journal of Gastroenterology 113, no. 2 (2018): 175-194.

[187] H. K. Seitz, R. Bataller, H. Cortez-Pinto, et al., “Alcoholic Liver Disease,” Nature Reviews Disease Primers 4, no. 1 (2018): 16.

[188] B. P. Lee, E. Vittinghoff, J. L. Dodge, et al., “National Trends and Long-term Outcomes of Liver Transplant for Alcohol-Associated Liver Disease in the United States,” JAMA Internal Medicine 179, no. 3 (2019): 340-348.

[189] N. Hosseini, J. Shor, and G. Szabo, “Alcoholic hepatitis: A Review,” Alcohol and Alcoholism 54, no. 4 (2019): 408-416.

[190] P. Kasper, S. Lang, H. Steffen, et al., “Management of Alcoholic hepatitis: A Clinical Perspective,” Liver International 43, no. 10 (2023): 2078-2095.

[191] M. R. Thursz, P. Richardson, M. Allison, et al., “Prednisolone or Pentoxifylline for Alcoholic hepatitis,” New England Journal of Medicine 372, no. 17 (2015): 1619-1628.

[192] B. Gao, Y. Duan, S. Lang, et al., “Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host co-metabolism in Patients With Alcoholic hepatitis,” Hepatology Communications 4, no. 8 (2020): 1168-1182.

[193] L. Jiang, S. Lang, Y. Duan, et al., “Intestinal Virome in Patients With Alcoholic hepatitis,” Hepatology 72, no. 6 (2020): 2182-2196.

[194] S. Lang, Y. Duan, J. Liu, et al., “Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic hepatitis,” Hepatology 71, no. 2 (2020): 522-538.

[195] S. Lang, B. Fairfied, B. Gao, et al., “Changes in the Fecal Bacterial Microbiota Associated With Disease Severity in Alcoholic hepatitis Patients,” Gut Microbes 12, no. 1 (2020): 1785251.

[196] H. Chu, Y. Duan, S. Lang, et al., “The Candida albicans Exotoxin Candidalysin Promotes Alcohol-associated Liver Disease,” Journal of Hepatology 72, no. 3 (2020): 391-400.

[197] W. Zhong, X. Wei, L. Hao, et al., “Paneth Cell Dysfunction Mediates Alcohol-related Steatohepatitis Through Promoting Bacterial Translocation in Mice: Role of Zinc Deficiency,” Hepatology 71, no. 5 (2020): 1575-1591.

[198] P. Stärkel and B. Schnabl, “Bidirectional Communication Between Liver and Gut During Alcoholic Liver Disease,” Seminars in Liver Disease 36, no. 4 (2016): 331-339.

[199] S. Lang and B. Schnabl, “Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future,” Cell Host & Microbe 28, no. 2 (2020): 233-244.

[200] Y. Duan, H. Chu, K. Brandl, et al., “CRIg on Liver Macrophages Clears Pathobionts and Protects Against Alcoholic Liver Disease,” Nature Communications 12, no. 1 (2021): 7172.

[201] A. K. Singal and P. Mathurin, “Diagnosis and Treatment of Alcohol-associated Liver Disease: A Review,” Jama 326, no. 2 (2021): 165-176.

[202] R. Bataller, J. P. Arab, and V. H. Shah, “Alcohol-associated hepatitis,” New England Journal of Medicine 387, no. 26 (2022): 2436-2448.

[203] M. E. Rinella, J. V. Lazarus, V. Ratziu, et al., “A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature,” Hepatology 78, no. 6 (2023): 1966-1986.

[204] T. Huby and E. L. Gautier, “Immune Cell-mediated Features of Non-alcoholic Steatohepatitis,” Nature Reviews Immunology 22, no. 7 (2022): 429-443.

[205] H. Hagström, P. Nasr, M. Ekstedt, et al., “Fibrosis Stage but Not NASH Predicts Mortality and Time to Development of Severe Liver Disease in Biopsy-proven NAFLD,” Journal of Hepatology 67, no. 6 (2017): 1265-1273.

[206] A. J. Sanyal, M. L. Van Natta, J. Clark, et al., “Prospective Study of Outcomes in Adults With Nonalcoholic Fatty Liver Disease,” New England Journal of Medicine 385, no. 17 (2021): 1559-1569.

[207] S. Khanmohammadi, B. Ramos-Molina, and M. S. Kuchay, “NOD-Like Receptors in the Pathogenesis of Metabolic (dysfunction)-associated Fatty Liver Disease: Therapeutic Agents Targeting NOD-Like Receptors,” Diabetology & Metabolic Syndrome 17, no. 7 (2023): 102788.

[208] L. Yu, F. Gao, Y. Li, et al., “Role of Pattern Recognition Receptors in the Development of MASLD and Potential Therapeutic Applications,” Biomed Pharmacother Biomedecine Pharmacother 175 (2024): 116724.

[209] O. Krenkel and F. Tacke, “Liver Macrophages in Tissue Homeostasis and Disease,” Nature Reviews Immunology 17, no. 5 (2017): 306-321.

[210] K. Kazankov, S. M. D. Jørgensen, K. L. Thomsen, et al., “The Role of Macrophages in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis,” Nature reviews Gastroenterology & hepatology 16, no. 3 (2019): 145-159.

[211] J. S. Duffield, S. J. Forbes, C. M. Constandinou, et al., “Selective Depletion of Macrophages Reveals Distinct, Opposing Roles During Liver Injury and Repair,” Journal of Clinical Investigation 115, no. 1 (2005): 56-65.

[212] P. Ramachandran, R. Dobie, J. R. Wilson-Kanamori, et al., “Resolving the Fibrotic Niche of human Liver Cirrhosis at Single-cell Level,” Nature 575, no. 7783 (2019): 512-518.

[213] M. Parola and M. Pinzani, “Liver Fibrosis in NAFLD/NASH: From Pathophysiology towards Diagnostic and Therapeutic Strategies,” Molecular Aspects of Medicine 95 (2024): 101231.

[214] A. Iwata, J. Maruyama, S. Natsuki, et al., “Egr2 drives the Differentiation of Ly6Chi Monocytes Into Fibrosis-promoting Macrophages in Metabolic Dysfunction-associated Steatohepatitis in Mice,” Communications Biology 7, no. 1 (2024): 681.

[215] Q. Wang, H. Zhou, Q. Bu, et al., “Role of XBP1 in Regulating the Progression of Non-alcoholic Steatohepatitis,” Journal of Hepatology 77, no. 2 (2022): 312-325.

[216] T. Lan, F. Gao, Y. Cai, et al., “The Protein circPETH-147aa Regulates Metabolic Reprogramming in Hepatocellular Carcinoma Cells to Remodel Immunosuppressive Microenvironment,” Nature Communications 16, no. 1 (2025): 333.

[217] H. Guo, M. Wang, C. Ni, et al., “TREM2 promotes the Formation of a Tumor-supportive Microenvironment in Hepatocellular Carcinoma,” Journal of Experimental & Clinical Cancer Research 44, no. 1 (2025): 20.

[218] Z.-Z. Bai, H.-Y. Li, C.-H. Li, et al., “Retraction Note: M1 Macrophage-derived Exosomal MicroRNA-326 Suppresses Hepatocellular Carcinoma Cell Progression via Mediating NF-κB Signaling Pathway,” Nanoscale Research Letters 17, no. 1 (2022): 122.

[219] J. Zhao, H. Li, S. Zhao, et al., “Epigenetic Silencing of miR-144/451a Cluster Contributes to HCC Progression via Paracrine HGF/MIF-mediated TAM Remodeling,” Molecular cancer 20, no. 1 (2021): 46.

[220] L. Wang, Y.-Y. Hu, J.-L. Zhao, et al., “Targeted Delivery of miR-99b Reprograms Tumor-associated Macrophage Phenotype Leading to Tumor Regression,” Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e000517.

[221] Y.-L. Zhang, Q. Li, X.-M. Yang, et al., “SPON2 promotes M1-Like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin-Rho GTPase-Hippo Pathways,” Cancer Research 78, no. 9 (2018): 2305-2317.

[222] B. Zhou, Y. Yang, and C. Li, “SIRT1 inhibits Hepatocellular Carcinoma Metastasis by Promoting M1 Macrophage Polarization via NF-κB Pathway,” OncoTargets and Therapy 12 (2019): 2519-2529.

[223] B. Zhou, C. Li, Y. Yang, et al., “RIG-I Promotes Cell Death in Hepatocellular Carcinoma by Inducing M1 Polarization of Perineal Macrophages Through the RIG-I/MAVS/NF-κB Pathway,” OncoTargets and Therapy 13 (2020): 8783-8794.

[224] Q. Wang, F. Cheng, T.-T. Ma, et al., “Interleukin-12 Inhibits the Hepatocellular Carcinoma Growth by Inducing Macrophage Polarization to the M1-Like Phenotype Through Downregulation of Stat-3,” Molecular and Cellular Biochemistry 415, no. 1-2 (2016): 157-168.

[225] O. W. H. Yeung, C.-M. Lo, C.-C. Ling, et al., “Alternatively Activated (M2) Macrophages Promote Tumour Growth and Invasiveness in Hepatocellular Carcinoma,” Journal of Hepatology 62, no. 3 (2015): 607-616.

[226] F. Zhu, X. Li, S. Chen, et al., “Tumor-associated Macrophage or Chemokine Ligand CCL17 Positively Regulates the Tumorigenesis of Hepatocellular Carcinoma,” Medical Oncology 33, no. 2 (2016): 17.

[227] D. Sun, T. Luo, P. Dong, et al., “M2-polarized Tumor-associated Macrophages Promote Epithelial-mesenchymal Transition via Activation of the AKT3/PRAS40 Signaling Pathway in Intrahepatic Cholangiocarcinoma,” Journal of Cellular Biochemistry 121, no. 4 (2020): 2828-2838.

[228] H. Yuan, Z. Lin, Y. Liu, et al., “Intrahepatic Cholangiocarcinoma Induced M2-polarized Tumor-associated Macrophages Facilitate Tumor Growth and Invasiveness,” Cancer cell international 20, no. 1 (2020): 586.

[229] C. Subimerb, S. Pinlaor, V. Lulitanond, et al., “Circulating CD14(+) CD16(+) Monocyte Levels Predict Tissue Invasive Character of Cholangiocarcinoma,” Clinical and Experimental Immunology 161, no. 3 (2010): 471-479.

[230] H. Hasita, Y. Komohara, H. Okabe, et al., “Significance of Alternatively Activated Macrophages in Patients With Intrahepatic Cholangiocarcinoma,” Cancer Science 101, no. 8 (2010): 1913-1919.

[231] Y. Zhang, C. Yan, Y. Dong, et al., “ANGPTL3 accelerates Atherosclerotic Progression via Direct Regulation of M1 Macrophage Activation in Plaque,” Journal of Advanced Research (2024). S2090-1232(24)00201-7.

[232] A. Das, F. Reis, and P. K. Mishra, “mTOR Signaling in Cardiometabolic Disease, Cancer, and Aging 2018,” Oxidative Medicine and Cellular Longevity 2019 (2019): 9692528.

[233] D. Ai, H. Jiang, M. Westerterp, et al., “Disruption of Mammalian Target of Rapamycin Complex 1 in Macrophages Decreases Chemokine Gene Expression and Atherosclerosis,” Circulation Research 114, no. 10 (2014): 1576-1584.

[234] X. Zhang, I. Sergin, T. D. Evans, et al., “High-protein Diets Increase Cardiovascular Risk by Activating Macrophage mTOR to Suppress Mitophagy,” Nature Metabolism 2, no. 1 (2020): 110-125.

[235] X. Zhang, J. G. McDonald, B. Aryal, et al., “Desmosterol Suppresses Macrophage Inflammasome Activation and Protects Against Vascular Inflammation and Atherosclerosis,” PNAS 118, no. 47 (2021): e2107682118.

[236] A. Canfrán-Duque, N. Rotllan, X. Zhang, et al., “Macrophage-derived 25-hydroxycholesterol Promotes Vascular Inflammation, Atherogenesis, and Lesion Remodeling,” Circulation 147, no. 5 (2023): 388-408.

[237] H. Wang, W. Mehal, L. E. Nagy, et al., “Immunological Mechanisms and Therapeutic Targets of Fatty Liver Diseases,” Cellular & Molecular Immunology 18, no. 1 (2021): 73-91.

[238] Z. Du, Y. Wang, J. Liang, et al., “Association of Glioma CD44 Expression With Glial Dynamics in the Tumour Microenvironment and Patient Prognosis,” Computational and Structural Biotechnology Journal 20 (2022): 5203-5217.

[239] C. Baeck, A. Wehr, K. R. Karlmark, et al., “Pharmacological Inhibition of the Chemokine CCL2 (MCP-1) Diminishes Liver Macrophage Infiltration and Steatohepatitis in Chronic Hepatic Injury,” Gut 61, no. 3 (2012): 416-426.

[240] M. Baba, H. Miyake, X. Wang, et al., “Isolation and Characterization of human Immunodeficiency Virus Type 1 Resistant to the Small-molecule CCR5 Antagonist TAK-652,” Antimicrobial Agents and Chemotherapy 51, no. 2 (2007): 707-715.

[241] A. Ambade, P. Lowe, K. Kodys, et al., “Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice,” Hepatology (Baltimore, Md.) 69, no. 3 (2019): 1105-1121.

[242] O. Krenkel, T. Puengel, O. Govaere, et al., “Therapeutic Inhibition of Inflammatory Monocyte Recruitment Reduces Steatohepatitis and Liver Fibrosis,” Hepatology (Baltimore, Md.) 67, no. 4 (2018): 1270-1283.

[243] Y. Guo, C. Zhao, W. Dai, et al., “C-C Motif Chemokine Receptor 2 Inhibition Reduces Liver Fibrosis by Restoring the Immune Cell Landscape,” International Journal of Biological Sciences 19, no. 8 (2023): 2572-2587.

[244] Q. M. Anstee, B. A. Neuschwander-Tetri, V. Wai-Sun Wong, et al., “Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study,” Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 22, no. 1 (2024): 124-134. e1.

[245] L. Fan, R. Lai, N. Ma, et al., “miR-552-3p Modulates Transcriptional Activities of FXR and LXR to Ameliorate Hepatic Glycolipid Metabolism Disorder,” Journal of Hepatology 74, no. 1 (2021): 8-19.

[246] L. Parlati, M. Régnier, H. Guillou, et al., “New Targets for NAFLD,” JHEP Reports: Innovation in Hepatology 3, no. 6 (2021): 100346.

[247] R. Liu, M. Scimeca, Q. Sun, et al., “Harnessing Metabolism of Hepatic Macrophages to Aid Liver Regeneration,” Cell Death & Disease 14, no. 8 (2023): 574.

[248] X. Han, Y. Wu, Q. Yang, et al., “Peroxisome Proliferator-activated Receptors in the Pathogenesis and Therapies of Liver Fibrosis,” Pharmacology & Therapeutics 222 (2021): 107791.

[249] A. Nikam, J. V. Patankar, M. Somlapura, et al., “The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-Like Hepatotoxicity,” Scientific Reports 8, no. 1 (2018): 12964.

[250] B. Staels, A. Rubenstrunk, B. Noel, et al., “Hepatoprotective Effects of the Dual Peroxisome Proliferator-activated Receptor Alpha/Delta Agonist, GFT505, in Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis,” Hepatology (Baltimore, Md.) 58, no. 6 (2013): 1941-1952.

[251] W. Deng, Z. Meng, A. Sun, et al., “Pioglitazone Suppresses Inflammation and Fibrosis in Nonalcoholic Fatty Liver Disease by Down-regulating PDGF and TIMP-2: Evidence From in Vitro Study,” Cancer Biomarkers: Section A of Disease Markers 20, no. 4 (2017): 411-415.

[252] D. Shen, H. Li, R. Zhou, et al., “Pioglitazone Attenuates Aging-related Disorders in Aged Apolipoprotein E Deficient Mice,” Experimental Gerontology 102 (2018): 101-108.

[253] V. Ratziu, S. A. Harrison, S. Francque, et al., “Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis without Fibrosis Worsening,” Gastroenterology 150, no. 5 (2016): 1147-1159. e5.

[254] K. Iwaisako, M. Haimerl, Y.-H. Paik, et al., “Protection From Liver Fibrosis by a Peroxisome Proliferator-activated Receptor δ Agonist,” PNAS 109, no. 21 (2012): E1369-1376.

[255] H.-J. Lim, J.-H. Park, S. Lee, et al., “PPARdelta Ligand L-165041 Ameliorates Western Diet-induced Hepatic Lipid Accumulation and Inflammation in LDLR-/- mice,” European Journal of Pharmacology 622, no. 1-3 (2009): 45-51.

[256] A. D. Patterson, Y. M. Shah, T. Matsubara, et al., “Peroxisome Proliferator-activated Receptor Alpha Induction of Uncoupling Protein 2 Protects Against Acetaminophen-induced Liver Toxicity,” Hepatology (Baltimore, Md.) 56, no. 1 (2012): 281-290.

[257] N. C. Teoh, J. Williams, J. Hartley, et al., “Short-term Therapy With Peroxisome Proliferation-activator Receptor-alpha Agonist Wy-14,643 Protects Murine Fatty Liver Against Ischemia-reperfusion Injury,” Hepatology (Baltimore, Md.) 51, no. 3 (2010): 996-1006.

[258] V. Ratziu, S. Francque, and A. Sanyal, “Breakthroughs in Therapies for NASH and Remaining Challenges,” Journal of Hepatology 76, no. 6 (2022): 1263-1278.

[259] A. M. Majzoub, T. Nayfeh, A. Barnard, et al., “Systematic Review With Network Meta-analysis: Comparative Efficacy of Pharmacologic Therapies for Fibrosis Improvement and Resolution of NASH,” Alimentary pharmacology & therapeutics 54, no. 7 (2021): 880-889.

[260] T. L. Laursen, A. Mellemkjær, H. J. Møller, et al., “Spotlight on Liver Macrophages for Halting Injury and Progression in Nonalcoholic Fatty Liver Disease,” Expert Opinion on Therapeutic Targets 26, no. 8 (2022): 697-705.

[261] T. Karagiannis, I. Avgerinos, A. Liakos, et al., “Management of Type 2 Diabetes With the Dual GIP/GLP-1 Receptor Agonist Tirzepatide: A Systematic Review and Meta-analysis,” Diabetologia 65, no. 8 (2022): 1251-1261.

[262] A. Mantovani, C. D. Byrne, and G. Targher, “Efficacy of Peroxisome Proliferator-activated Receptor Agonists, Glucagon-Like Peptide-1 Receptor Agonists, or Sodium-glucose Cotransporter-2 Inhibitors for Treatment of Non-alcoholic Fatty Liver Disease: A Systematic Review,” The Lancet Gastroenterology and Hepatology 7, no. 4 (2022): 367-378.

[263] J. M. Yabut and D. J. Drucker Endocrine Reviews 44, no. 1 (2023): 14-32.

[264] G. Targher, “Tirzepatide Adds Hepatoprotection to Its Armoury,” The Lancet Diabetes & Endocrinology 10, no. 6 (2022): 374-375.

[265] J. M. Yabut and D. J. Drucker, “Glucagon-Like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease,” Endocrine Reviews 44, no. 1 (2023): 14-32.

[266] N. Song, H. Xu, J. Liu, et al., “Design of a Highly Potent GLP-1R and GCGR Dual-agonist for Recovering Hepatic Fibrosis,” Acta Pharmaceutica Sinica B 12, no. 5 (2022): 2443-2461.

[267] Y. Peng, H. Lin, S. Tian, et al., “Glucagon-Like Peptide-1 Receptor Activation Maintains Extracellular Matrix Integrity by Inhibiting the Activity of Mitogen-activated Protein Kinases and Activator Protein-1,” Free Radical Biology and Medicine 177 (2021): 247-259.

[268] R. Bruen, S. Curley, S. Kajani, et al., “Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis,” Cardiovascular Diabetology 16, no. 1 (2017). https://doi.org/10.1186/s12933-017-0626-3.

[269] Á. Vinué, J. Navarro, A. Herrero-Cervera, et al., “The GLP-1 Analogue Lixisenatide Decreases Atherosclerosis in Insulin-resistant Mice by Modulating Macrophage Phenotype,” Diabetologia 60, no. 9 (2017): 1801-1812.

[270] P. N. Newsome and P. Ambery, “Incretins (GLP-1 receptor agonists and dual/triple agonists) and the Liver,” Journal of Hepatology 79, no. 6 (2023): 1557-1565.

[271] R. Nevola, R. Epifani, S. Imbriani, et al., “GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives,” International Journal of Molecular Sciences 24, no. 2 (2023): 1703.

[272] F. Yang, X. Luo, J. Li, et al., “Application of Glucagon-Like Peptide-1 Receptor Antagonists in Fibrotic Diseases,” Biomed Pharmacother Biomedecine Pharmacother 152 (2022): 113236.

[273] J. H. D. Bassett and G. R. Williams, “The Molecular Actions of Thyroid Hormone in Bone,” Trends in Endocrinology & Metabolism 14, no. 8 (2003): 356-364.

[274] S. A. Harrison, M. R. Bashir, C. D. Guy, et al., “Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Trial,” Lancet Lond Engl 394, no. 10213 (2019): 2012-2024.

[275] T. Puengel, H. Liu, A. Guillot, et al., “Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease,” International Journal of Molecular Sciences 23, no. 5 (2022): 2668.

[276] X. Wang, L. Wang, L. Geng, et al., “Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner,” International Journal of Molecular Sciences 24, no. 6 (2023): 5843.

[277] S. A. Kliewer and D. J. Mangelsdorf, “Fibroblast Growth Factor 21: From Pharmacology to Physiology,” American Journal of Clinical Nutrition 91, no. 1 (2010): 254S-257S.

[278] Y. Liu, C. Zhao, J. Xiao, et al., “Fibroblast Growth Factor 21 Deficiency Exacerbates Chronic Alcohol-induced Hepatic Steatosis and Injury,” Scientific Reports 6 (2016): 31026.

[279] R. Loomba, A. J. Sanyal, K. V. Kowdley, et al., “Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH,” New England Journal of Medicine 389, no. 11 (2023): 998-1008.

[280] K. H. Flippo, S. A. J. Trammell, M. P. Gillum, et al., “FGF21 suppresses Alcohol Consumption Through an Amygdalo-striatal Circuit,” Cell metabolism 34, no. 2 (2022): 317-328. e6.

[281] C. Liu, M. Schönke, B. Spoorenberg, et al., “FGF21 protects Against Hepatic Lipotoxicity and Macrophage Activation to Attenuate Fibrogenesis in Nonalcoholic Steatohepatitis,” Elife 12 (2023): e83075.

[282] M. Cariello and A. Moschetta, “Fibroblast Growth Factor 21: A New Liver Safeguard,” Hepatology (Baltimore, Md.) 60, no. 3 (2014): 792-794.

[283] N. Tanaka, S. Takahashi, Y. Zhang, et al., “Role of Fibroblast Growth Factor 21 in the Early Stage of NASH Induced by Methionine- and Choline-deficient Diet,” Biochimica Et Biophysica Acta 1852, no. 7 (2015): 1242-1252.

[284] F. M. Fisher, P. C. Chui, I. A. Nasser, et al., “Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-deficient Diets,” Gastroenterology 147, no. 5 (2014): 1073-1083. e6.

[285] X. Yang, Z. Jin, D. Lin, et al., “FGF21 alleviates Acute Liver Injury by Inducing the SIRT1-autophagy Signalling Pathway,” Journal of Cellular and Molecular Medicine 26, no. 3 (2022): 868-879.

[286] X. Wan, X. Lu, Y. Xiao, et al., “ATF4- and CHOP-dependent Induction of FGF21 Through Endoplasmic Reticulum Stress,” BioMed research international 2014 (2014): 807874.

[287] S. Jiang, C. Yan, Q. Fang, et al., “Fibroblast Growth Factor 21 Is Regulated by the IRE1α-XBP1 Branch of the Unfolded Protein Response and Counteracts Endoplasmic Reticulum Stress-induced Hepatic Steatosis,” Journal of Biological Chemistry 289, no. 43 (2014): 29751-29765.

[288] L. Wu, Q. Pan, G. Wu, et al., “Diverse Changes of Circulating Fibroblast Growth Factor 21 Levels in Hepatitis B Virus-Related Diseases,” Scientific Reports 7, no. 1 (2017): 16482.

[289] D. Ye, Y. Wang, H. Li, et al., “Fibroblast Growth Factor 21 Protects Against Acetaminophen-induced Hepatotoxicity by Potentiating Peroxisome Proliferator-activated Receptor Coactivator Protein-1α-mediated Antioxidant Capacity in Mice,” Hepatology (Baltimore, Md.) 60, no. 3 (2014): 977-989.

[290] D. Ye, H. Li, Y. Wang, et al., “Circulating Fibroblast Growth Factor 21 Is a Sensitive Biomarker for Severe Ischemia/Reperfusion Injury in Patients With Liver Transplantation,” Scientific Reports 6 (2016): 19776.

[291] R. Loomba, E. J. Lawitz, J. P. Frias, et al., “Safety, Pharmacokinetics, and Pharmacodynamics of pegozafermin in Patients With Non-alcoholic Steatohepatitis: A Randomised, Double-blind, Placebo-controlled, Phase 1b/2a Multiple-ascending-dose Study,” The Lancet Gastroenterology and Hepatology 8, no. 2 (2023): 120-132.

[292] A. C. Mackinnon, D. Tonev, B. Jacoby, et al., “Galectin-3: Therapeutic Targeting in Liver Disease,” Expert Opinion on Therapeutic Targets 27, no. 9 (2023): 779-791.

[293] H. Liu, L. Zhang, Z. Liu, et al., “Galectin-3 as TREM2 Upstream Factor Contributes to Lung Ischemia-reperfusion Injury by Regulating Macrophage Polarization,” Iscience 26, no. 9 (2023): 107496.

[294] H. Li, Z. Cao, L. Wang, et al., “Chronic High-fat Diet Induces Galectin-3 and TLR4 to Activate NLRP3 Inflammasome in NASH,” Journal of Nutritional Biochemistry 112 (2023): 109217.

[295] S. A. de Oliveira, B. S. de Freitas Souza, E. P. Sá Barreto, et al., “Reduction of Galectin-3 Expression and Liver Fibrosis After Cell Therapy in a Mouse Model of Cirrhosis,” Cytotherapy 14, no. 3 (2012): 339-349.

[296] L. Li, J. Li, and J. Gao, “Functions of Galectin-3 and Its Role in Fibrotic Diseases,” Journal of Pharmacology and Experimental Therapeutics 351, no. 2 (2014): 336-343.

[297] N. C. Henderson, A. C. Mackinnon, S. L. Farnworth, et al., “Galectin-3 Regulates Myofibroblast Activation and Hepatic Fibrosis,” PNAS 103, no. 13 (2006): 5060-5065.

[298] S. A. Harrison, A. Dennis, M. M. Fiore, et al., “Utility and Variability of Three Non-invasive Liver Fibrosis Imaging Modalities to Evaluate Efficacy of GR-MD-02 in Subjects With NASH and Bridging Fibrosis During a Phase-2 Randomized Clinical Trial,” PLoS ONE 13, no. 9 (2018): e0203054.

[299] A. C. MacKinnon, S. L. Farnworth, P. S. Hodkinson, et al., “Regulation of Alternative Macrophage Activation by Galectin-3,” Journal of Immunology (Baltimore, Md.: 1950) 180, no. 4 (2008): 2650-2658.

[300] A. Arsenijevic, J. Milovanovic, B. Stojanovic, et al., “Gal-3 Deficiency Suppresses Novosphyngobium Aromaticivorans Inflammasome Activation and IL-17 Driven Autoimmune Cholangitis in Mice,” Frontiers in Immunology 10 (2019): 1309.

[301] B. Simovic Markovic, A. Nikolic, M. Gazdic, et al., “Galectin-3 Plays an Important Pro-inflammatory Role in the Induction Phase of Acute Colitis by Promoting Activation of NLRP3 Inflammasome and Production of IL-1β in Macrophages,” Journal of Crohn's and Colitis 10, no. 5 (2016): 593-606.

[302] F. R. Zetterberg, A. MacKinnon, T. Brimert, et al., “Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease,” Journal of Medicinal Chemistry 65, no. 19 (2022): 12626-12638.

[303] J. Zhao, Y.-C. Fan, X.-Y. Liu, et al., “Hypermethylation of the Galectin-3 Promoter Is Associated With Poor Prognosis of Acute-on-chronic hepatitis B Liver Failure,” Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver 49, no. 6 (2017): 664-671.

[304] M. Matsuo, A. Kanbe, K. Noguchi, et al., “Time-course Analysis of Liver and Serum Galectin-3 in Acute Liver Injury After Alpha-galactosylceramide Injection,” PLoS ONE 19, no. 2 (2024): e0298284.

[305] S. A. Harrison, V. W.-S. Wong, T. Okanoue, et al., “Selonsertib for Patients With Bridging Fibrosis or Compensated Cirrhosis due to NASH: Results From Randomized Phase III STELLAR Trials,” Journal of Hepatology 73, no. 1 (2020): 26-39.

[306] T. Lan, Y. Hu, F. Hu, et al., “Hepatocyte Glutathione S-transferase Mu 2 Prevents Non-alcoholic Steatohepatitis by Suppressing ASK1 Signaling,” Journal of Hepatology 76, no. 2 (2022): 407-419.

[307] Y. Jiao, P. Xu, H. Shi, et al., “Advances on Liver Cell-derived Exosomes in Liver Diseases,” Journal of Cellular and Molecular Medicine 25, no. 1 (2021): 15-26.

[308] T. Liwinski, M. Heinemann, and C. Schramm, “The Intestinal and Biliary Microbiome in Autoimmune Liver Disease-current Evidence and Concepts,” Seminars in Immunopathology 44, no. 4 (2022): 485-507.

[309] C. A. Mecoli, T. Igusa, M. Chen, et al., “Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population,” Arthritis & Rheumatology (Hoboken, N.J.) 75, no. 4 (2023): 620-629.

[310] Y. H. Lee, H.-J. Jang, S. Kim, et al., “Hepatic MIR20B Promotes Nonalcoholic Fatty Liver Disease by Suppressing PPARA,” Elife 10 (2021): e70472.

[311] X. Zhang, J. Shen, K. Man, et al., “CXCL10 plays a Key Role as an Inflammatory Mediator and a Non-invasive Biomarker of Non-alcoholic Steatohepatitis,” Journal of Hepatology 61, no. 6 (2014): 1365-1375.

[312] L. Grønbæk, H. Vilstrup, and P. Jepsen, “Autoimmune hepatitis in Denmark: Incidence, Prevalence, Prognosis, and Causes of Death. A Nationwide Registry-based Cohort Study,” Journal of Hepatology 60, no. 3 (2014): 612-617.

[313] L. Grønbaek, H. Otete, L. Ban, et al., “Incidence, Prevalence and Mortality of Autoimmune hepatitis in England 1997-2015. A Population-based Cohort Study,” Liver Int Off J Int Assoc Study Liver 40, no. 7 (2020): 1634-1644.

[314] G. J. Webb, R. P. Ryan, T. P. Marshall, et al., “The Epidemiology of UK Autoimmune Liver Disease Varies with Geographic Latitude,” Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 19, no. 12 (2021): 2587-2596.

[315] P. Muratori, C. Lalanne, E. Barbato, et al., “Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy,” Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 14, no. 1 (2016): 139-146.

[316] L. Grønbaek, H. Vilstrup, L. Pedersen, et al., “Extrahepatic Autoimmune Diseases in Patients With Autoimmune hepatitis and Their Relatives: A Danish Nationwide Cohort Study,” Liver Int Off J Int Assoc Study Liver 39, no. 1 (2019): 205-214.

[317] S. Lefere, T. Puengel, J. Hundertmark, et al., “Differential Effects of Selective- and Pan-PPAR Agonists on Experimental Steatohepatitis and Hepatic Macrophages☆,” Journal of Hepatology 73, no. 4 (2020): 757-770.

[318] P. Muratori, A. Fabbri, C. Lalanne, et al., “Autoimmune Liver Disease and Concomitant Extrahepatic Autoimmune Disease,” European Journal of Gastroenterology & Hepatology 27, no. 10 (2015): 1175-1179.

[319] Y. Cheng, P. Zhu, J. Yang, et al., “Ischaemic Preconditioning-regulated miR-21 Protects Heart Against Ischaemia/Reperfusion Injury via Anti-apoptosis Through Its Target PDCD4,” Cardiovascular Research 87, no. 3 (2010): 431-439.

[320] Z. Li, P.-P. Feng, Z.-B. Zhao, et al., “Liraglutide Protects Against Inflammatory Stress in Non-alcoholic Fatty Liver by Modulating Kupffer Cells M2 Polarization via cAMP-PKA-STAT3 Signaling Pathway,” Biochemical and Biophysical Research Communications 510, no. 1 (2019): 20-26.

[321] F. Tacke, T. Puengel, R. Loomba, et al., “An Integrated View of Anti-inflammatory and Antifibrotic Targets for the Treatment of NASH,” Journal of Hepatology 79, no. 2 (2023): 552-566.

[322] M. Vuerich, R. Harshe, L. A. Frank, et al., “Altered Aryl-hydrocarbon-receptor Signalling Affects Regulatory and Effector Cell Immunity in Autoimmune hepatitis,” Journal of Hepatology 74, no. 1 (2021): 48-57.

[323] M. Mendizabal, S. Marciano, M. G. Videla, et al., “Fulminant Presentation of Autoimmune hepatitis: Clinical Features and Early Predictors of Corticosteroid Treatment Failure,” European Journal of Gastroenterology & Hepatology 27, no. 6 (2015): 644-648.

[324] Y. Ni, F. Zhuge, L. Ni, et al., “CX3CL1/CX3CR1 interaction Protects Against Lipotoxicity-induced Nonalcoholic Steatohepatitis by Regulating Macrophage Migration and M1/M2 Status,” Metabolism 136 (2022): 155272.

[325] F. Xu, M. Guo, W. Huang, et al., “Annexin A5 Regulates Hepatic Macrophage Polarization via Directly Targeting PKM2 and Ameliorates NASH,” Redox Biology 36 (2020): 101634.

[326] W. Luo, Q. Xu, Q. Wang, et al., “Effect of Modulation of PPAR-γ Activity on Kupffer Cells M1/M2 Polarization in the Development of Non-alcoholic Fatty Liver Disease,” Scientific Reports 7 (2017): 44612.

[327] N. Sonthalia, P. M. Rathi, S. S. Jain, et al., “Natural History and Treatment Outcomes of Severe Autoimmune Hepatitis,” Journal of Clinical Gastroenterology 51, no. 6 (2017): 548-556.

[328] X. Qu, T. Yang, X. Wang, et al., “Macrophage RIPK3 Triggers Inflammation and Cell Death via the XBP1-Foxo1 Axis in Liver Ischaemia-reperfusion Injury,” JHEP Reports: Innovation in Hepatology 5, no. 11 (2023): 100879.

[329] K. Newton, D. L. Dugger, A. Maltzman, et al., “RIPK3 deficiency or Catalytically Inactive RIPK1 Provides Greater Benefit Than MLKL deficiency in Mouse Models of Inflammation and Tissue Injury,” Cell Death and Differentiation 23, no. 9 (2016): 1565-1576.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.